US 12,268,700 B2
3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof
Lise H. Pasquet, Saint-Pierre-du-Mont (FR); Jay A. Berzofsky, Bethesda, MD (US); Amy R. Howell, Storrs, CT (US); Masaki Terabe, Potomac, MD (US); Kaddy Camara, Storrs, CT (US); and Stewart K. Richardson, Storrs, CT (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and University of Connecticut, Farmington, CT (US)
Appl. No. 17/041,604
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and University of Connecticut, Farmington, CT (US)
PCT Filed Mar. 25, 2019, PCT No. PCT/US2019/023890
§ 371(c)(1), (2) Date Sep. 25, 2020,
PCT Pub. No. WO2019/190986, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/648,167, filed on Mar. 26, 2018.
Prior Publication US 2021/0023110 A1, Jan. 28, 2021
Int. Cl. A61K 31/7032 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07H 15/04 (2006.01); C07H 15/10 (2006.01)
CPC A61K 31/7032 (2013.01) [A61K 38/1774 (2013.01); A61K 38/193 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07H 15/04 (2013.01); C07H 15/10 (2013.01)] 5 Claims
 
1. A compound of the formula (Ic) or (IIc):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.